CSIMarket Company Name, Ticker, Customers, else..
 
Forte Biosciences Inc   (NASDAQ: FBRX)
 
Price: $76.9900 $76.99 %
Day's High: $76.98999786376953 Week Perf: 0.05 %
Day's Low: $ 76.99 30 Day Perf: 0.01 %
Volume (M): 0 52 Wk High: $ 77.34
Volume (M$): $ 0 52 Wk Avg: $29.82
Open: $76.99 52 Wk Low: $10.30



 Market Capitalization (Millions $) 1,634
 Shares Outstanding (Millions) 21
 Employees 23
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0

Business Description


Forte Biosciences Inc is a biotechnology company that focuses on developing novel treatments for dermatological conditions. Their research and development efforts primarily revolve around harnessing the potential of the human microbiome to develop safe and effective therapeutic products. The company aims to address unmet needs in dermatology by developing microbiome-based treatments that can restore the balance of the skin microbiome and improve skin health. Forte Biosciences Inc is committed to advancing innovative solutions for various skin conditions and improving the quality of life for patients.


   Company Address: 3060 Pegasus Park Drive, Building 6 Dallas 75247 TX
   Company Phone Number: 618-6994   Stock Exchange / Ticker: NASDAQ FBRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -0.6%    
ONC        3.27% 
REGN   -1.32%    
TEVA        8.2% 
VRTX   -0.28%    
VTRS        5.28% 
• View Complete Report
   



Business Update

Forte Biosciences Reports Positive Progress in Q2 2024; Advances FB102 Monoclonal Antibody Therapeutic Candidate

Published Thu, Aug 15 2024 5:37 AM UTC

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company headquartered in Dallas, has announced significant developments in its operations during the second quarter of 2024, along with comprehensive financial results for the period. Since its inception, Forte has focused its efforts on addressing the unmet medical needs presented by autoimmune and autoimmune-relat...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 8.89
PEG (TTM) -

Financial Strength Current
Quick Ratio 17.12
Working Capital Ratio 17.37
Leverage Ratio (MRQ) 0.12
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.59 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 16.36 $
Book Value 8.66 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,823,348
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.